Keros Therapeutics, Inc.

NASDAQ:KROS

14.57 (USD) • At close May 23, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 211.2463.0420.3880.0370.0830.1430.00800000.102000.1000002.52.52.52.5
Cost of Revenue 0000.3060.2770.2470.5510.5450.6890.4480.3370.5140.3160.3020.2239.9830.1799.6740004.13000
Gross Profit 211.2462.710.388-0.269-0.194-0.104-0.543-0.545-0.689-0.448-0.337-0.414-0.31619.698-0.223-9.883-0.179-9.674000-1.63000
Gross Profit Ratio 10.8911-7.27-2.337-0.727-67.8750000-4.1400.9850-98.8300000-0.652000
Reseach & Development Expenses 48.70945.63149.22540.51538.25837.49334.1432.53431.09124.86721.03923.28118.07818.83414.8329.98311.4959.6748.3957.2648.5274.1613.8544.4974.867
General & Administrative Expenses 10.49710.6659.829.96110.3089.1059.1488.8037.7787.0936.9377.4476.0486.0335.3655.6584.2743.6173.5533.651.9771.0670.9720.6540.491
Selling & Marketing Expenses 000-0.306000000000000000000000
SG&A 10.49710.6659.829.65510.3089.1059.1488.8037.7787.0936.9377.4476.0486.0335.3655.6584.2743.6173.5533.651.9771.0670.9720.6540.491
Other Expenses 000-0.196-0.437-10.9433.843.8323.0652.242-3.705-3.376-0.059-0.074-0.137-0.08-0.0650.156000-0.022000
Operating Expenses 59.20656.29659.04550.1748.56644.19843.28841.33738.86931.9624.27127.35224.12624.86720.19715.64115.76910.83111.94810.91410.5045.2284.8265.1515.358
Operating Income 152.04-53.254-58.657-50.439-48.483-46.455-43.28-41.337-38.869-31.96-27.976-30.728-24.126-4.867-20.197-15.541-15.769-13.291-11.948-10.914-10.504-2.728-2.326-2.651-2.858
Operating Income Ratio 0.72-17.506-151.178-1,363.216-584.133-324.86-5,4100000-307.280-0.2430-155.4100000-1.091-0.93-1.06-1.143
Total Other Income Expenses Net 6.4547.5285.7015.1825.3696.2123.843.8323.0652.2424.4673.462-0.06-0.075-0.138-0.081-0.0662.615-0.0880.157-1.56-0.023-1.223-0.202-0.325
Income Before Tax 158.494-45.726-52.956-45.257-43.114-40.243-39.44-37.505-35.804-29.718-23.509-27.266-24.186-4.942-20.335-15.622-15.835-10.676-12.036-10.757-12.064-2.751-3.549-2.853-3.183
Income Before Tax Ratio 0.75-15.032-136.485-1,223.162-519.446-281.42-4,9300000-272.660-0.2470-156.2200000-1.1-1.42-1.141-1.273
Income Tax Expense 10.0430.300-0.2773.812-0.213.832-3.0650.002-4.467-3.4620.0011.998-0.038-0.0790.050.08200-0.1722.302000
Net Income 148.451-46.026-52.956-45.257-43.114-40.243-39.44-37.505-32.739-29.72-19.042-23.804-24.187-6.94-20.297-15.622-15.885-10.676-12.036-10.757-11.892-2.751-3.549-2.853-3.183
Net Income Ratio 0.703-15.13-136.485-1,223.162-519.446-281.42-4,9300000-238.040-0.3470-156.2200000-1.1-1.42-1.141-1.273
EPS 3.66-1.14-1.47-1.25-1.46-1.34-1.33-1.27-1.15-1.09-0.75-0.99-1.01-0.3-0.87-0.67-0.68-0.49-0.597-0.622-0.698-0.31-0.45-0.372-0.409
EPS Diluted 3.62-1.14-1.47-1.25-1.46-1.34-1.33-1.27-1.15-1.09-0.75-0.99-1.01-0.3-0.87-0.67-0.68-0.49-0.597-0.622-0.698-0.31-0.45-0.372-0.409
EBITDA 152.384-46.632-58.657-50.133-48.206-39.996-43.07-41.146-38.869-29.27-20.197-30.128-24.072-4.639-20.197-15.428-15.769-10.502-11.962-10.688-11.999-0.368-3.491-2.224-2.633
EBITDA Ratio 0.721-15.329-151.178-1,354.946-580.795-279.692-5,383.750000-301.280-0.2320-154.2800000-0.147-1.396-0.89-1.053